Eagle Pharmaceuticals Priced, Nasdaq: EGRX
Develops and sells enhanced injectable versions of expiring patented drugs.
Industry: Health Care
First Day Return: -14.5%
EGRX
Develops and sells enhanced injectable versions of expiring patented drugs.
| IPO Data | |
|---|---|
| IPO Date | 02/11/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Woodcliff Lake, NJ, United States |
| Founded | 2007 |
| Employees at IPO | 20 |
| Website www.eagleus.com | |
IPO News for Eagle Pharmaceuticals
Eagle Pharmaceuticals (EGRX) Performance
